EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Assessment and management of fracture risk in men with prostate cancer taking androgen deprivation therapy: a retrospective observational primary care database study

Qizhi Huang, Janet Brown, Caroline Mitchell

British Journal of General Practice · 2024

DOI: 10.3399/bjgp24x737637 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of General Practice, 2024. Verfasst von Qizhi Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: The University of Sheffield. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists, Osteoporotic Fractures, Primary Health Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate Cancer (PCa) is the commonest cancer in the UK. Androgen deprivation therapy (ADT) is a mainstay of treatment. It increases fragility fractures causing a huge burden to patients and the NHS. As men live longer with PCa, many require prolonged ADT. Reducing fracture risks and improving cancer survivorship is becoming increasingly important. Primary care plays an important role.

Aim

To evaluate how fracture risk of PCa patients taking ADT (PCa-ADT) was assessed and managed in primary care.

Method

A retrospective multi-practice database study. PCa patients were identified using SNOMED codes from five sociodemographically diverse practices (registered population 49 400). Data were extracted by hand-searching records, including hospital letters, and included: demographics; a 10-year fragility fracture score (FRAX); NOGG intervention threshold; DEXA requests; and use of bisphosphonates.

Results

Of the 261 PCa patients identified, 6% were Black African/Caribbean and 89% White British. Half had been prescribed ADT, 28% being current users. No fracture risk assessment was documented for any patients. ADT current users had significantly increased FRAX scores for both major osteoporotic fractures (MOF) (9.61%±1.12%) and hip fracture (HF) (5.30%±1.02%) compared with PCa patients without ADT (7.08%±0.57% [MOF] and 3.06%±0.46% [HF], P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAndrogen AntagonistsOsteoporotic FracturesPrimary Health CareHumansMaleRetrospective StudiesAgedRisk AssessmentBone Density Conservation AgentsUnited KingdomMiddle AgedDiphosphonatesDatabases, FactualAbsorptiometry, PhotonOsteoporosisAged, 80 and overRisk Factors

Substanzen

Androgen AntagonistsBone Density Conservation AgentsDiphosphonates

Autor:innen und Institutionen

  • The University of Sheffield.

Zitieren

APA

Huang, Q., Brown, J., & Mitchell, C. (2024). Assessment and management of fracture risk in men with prostate cancer taking androgen deprivation therapy: a retrospective observational primary care database study. British Journal of General Practice. https://doi.org/10.3399/bjgp24x737637

Vancouver

Huang Q, Brown J, Mitchell C. Assessment and management of fracture risk in men with prostate cancer taking androgen deprivation therapy: a retrospective observational primary care database study. British Journal of General Practice. 2024. doi:10.3399/bjgp24x737637

BibTeX
@article{Huang2024,
  author = {Huang, Qizhi and Brown, Janet and Mitchell, Caroline},
  title = {Assessment and management of fracture risk in men with prostate cancer taking androgen deprivation therapy: a retrospective observational primary care database study},
  journal = {British Journal of General Practice},
  year = {2024},
  doi = {10.3399/bjgp24x737637}
}
Kostenlos starten →